Engflag

Atripla Access

Quick links to important sections

Atripla Access

Selected form

Atripla Access_EN

Treatment option: Infection

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atripla Access

Understanding Atripla Access

Atripla Access is a fixed-dose combination medication used in the management of human immunodeficiency virus type 1 (HIV-1). It combines three different antiretroviral agents into a single daily tablet: efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

Composition and Mechanism

The three components of Atripla Access belong to two different classes of antiretroviral drugs:

  • Efavirenz: A non-nucleoside reverse transcriptase inhibitor (NNRTI).
  • Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI).
  • Tenofovir Disoproxil Fumarate: A nucleoside reverse transcriptase inhibitor (NRTI).

These substances work together to interfere with the replication process of the virus. By targeting the reverse transcriptase enzyme, the medication helps to reduce the viral load in the body and maintain the health of the immune system, specifically by supporting CD4+ T-cell counts.

Therapeutic Intent

The primary goal of Atripla Access is to provide a complete regimen for HIV-1 treatment in a simplified format. While it is not a cure for HIV or AIDS, it is designed to control the progression of the virus. This combination therapy is intended for use in adults and pediatric patients who meet specific weight requirements, either as a standalone treatment or in combination with other antiretrovirals as determined by a healthcare provider.

What side effects are possible with Atripla Access?

Possible Side Effects and Safety Information

The safety profile for Atripla Access (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) is characterized by adverse reactions classified by frequency and system-organ class as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized based on incidence rates observed in clinical trials:

  • Very Common (Affecting ge 1 in 10 people): Headache, dizziness, diarrhea, nausea, fatigue, insomnia, depression, and abnormal dreams.
  • Common (Affecting ge 1 in 100 people): Vomiting, abdominal pain, somnolence (drowsiness), anxiety, pruritus (itching), and elevations in hepatic enzymes.

Serious Adverse Reactions and Systemic Concerns

Official documents highlight the potential for serious adverse reactions, which, while uncommon or rare, represent significant safety events:

  • Systemic Risk: The potential for Lactic Acidosis and Severe Hepatomegaly with Steatosis (enlargement of the liver with fat) is noted as a rare but serious risk associated with the nucleoside analog components.
  • Organ Function: Severe psychiatric symptoms (including suicidal ideation and severe depression), hepatic failure, and severe skin reactions (such as Stevens-Johnson syndrome) are documented as serious adverse reactions.
  • Renal Health: New onset or worsening renal impairment, including acute renal failure and Fanconi syndrome, is a safety consideration, particularly with the Tenofovir component.

Time-Related and Population Safety Patterns

The occurrence of certain effects is related to the timing of therapy. Nervous system symptoms (e.g., dizziness) are typically most frequent at the initiation of treatment and tend to diminish within the first two to four weeks. In contrast, decreases in bone mineral density (BMD) and the risk of renal dysfunction are associated with the long-term exposure to the medication.

The regulatory label specifies contraindications for patients with a known history of hypersensitivity to any component and for those with severe hepatic impairment. Use is also restricted in patients with significant pre-existing renal impairment (creatinine clearance below 50 mL/min).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose exposure to Atripla Access requires immediate emergency action and strict adherence to official regulatory guidance. The primary documented risk is related to acute Nervous System Symptoms (NSS), a dose-related effect of the Efavirenz component. Manifestations reported in cases of high exposure include specific clinical signs such as uncontrolled muscle movements. Severe neuropsychiatric outcomes, including reports of death by suicide following an overdose, are documented in post-marketing experience.

If an overdose is suspected, regulatory instructions mandate that you seek immediate medical attention or contact a certified Poison Control Center. No specific pharmacological antidote is documented in the prescribing information; therefore, management must consist of general supportive measures and symptomatic treatment. Required hospital procedures include continuous monitoring of vital signs and observation of the patient's clinical status. While the Emtricitabine and Tenofovir components are efficiently removed by hemodialysis, the highly protein-bound Efavirenz component is unlikely to be removed by this procedure. The official profile contains no differential management guidelines for specific patient populations.

Therapeutic Uses of Atripla Access

The primary therapeutic domain for Atripla Access is the management of Human Immunodeficiency Virus type 1 ( HIV-1) infection. The medication is generally used as a complete regimen for this chronic condition, relevant in adults and certain pediatric patients meeting specific weight requirements.

Core Uses and Patient Benefits

This Single Tablet Regimen ( STR) is commonly used for the long-term management of HIV-1 infection, applied in clinical settings that involve viral burden. The therapeutic goals include supporting the body during immune system deterioration and helping to maintain immune functional stability, which assists in reducing the risk of AIDS-defining illnesses. This approach may assist with general well-being during symptomatic periods.

The primary indications include the long-term treatment of chronic HIV-1 infection, and plays a role in managing the viral load goal of undetectable status, in addition to simplifying therapy for virologically suppressed patients switching from complex multi-pill regimens. The formulation may assist with patient adherence to the prescribed long-term therapy.

Quick Fact Block

Quick Fact: Relief for Treatment Burden Description
Primary Benefit The Single Tablet Regimen ( STR) design contributes to easing the overall symptom load related to treatment complexity.
Contextual Use Applied during phases when managing a combination regimen creates noticeable physiological strain or interferes with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Atripla Access

The eligibility for this fixed-dose combination medicine is strictly defined by regulatory criteria regarding patient population, organ function, and physiological status.

Eligibility Scope

Population Status Regulatory Rule
Contraindicated Patients with known hypersensitivity to any component; patients with severe hepatic impairment (Child-Pugh Class C).
Not Recommended Patients with moderate or severe renal impairment (estimated creatinine clearance < 50 mL/min).
Age Group Approved for adults and pediatric patients ge 12 years of age weighing at least 40 kg.
Pregnancy Not recommended during the first trimester; effective contraception is required for women of childbearing potential.
Co-administration Prohibited with any other product containing Efavirenz, Emtricitabine, or Tenofovir Disoproxil Fumarate.

Eligibility Classifications

Regulatory documents define specific use restrictions: the fixed-dose formulation cannot be adjusted for patients with renal impairment, leading to the not recommended classification in those with severe or moderate dysfunction. Use is also restricted in those with moderate hepatic impairment (Child-Pugh Class B). Breastfeeding is not recommended for mothers taking this medicine.

What should I know about interactions with other medicines?

The interaction profile of Atripla Access is strictly defined by the regulatory labeling for its three active components, resulting in mandatory restrictions and prohibitions for co-administration.

Interaction Classification Official Restrictions and Outcomes
Contraindicated Combinations Co-administration is prohibited with substances that pose a risk of therapeutic failure (e.g., Voriconazole, St. John's Wort) or severe adverse events (e.g., Ergot Alkaloids, Pimozide, Elbasvir/Grazoprevir).
Pharmacokinetic Alterations The Efavirenz component is a potent inducer of CYP3A4 and CYP2B6 enzymes, which significantly reduces the plasma concentrations of many co-administered drugs, including Hormonal Contraceptives and certain Anticonvulsants.
Pharmacodynamic Effects Caution is required for agents that may lead to additive CNS depression (e.g., Alcohol) or carry a risk of QTc prolongation. Co-administration with certain Protease Inhibitors (e.g., Lopinavir/Ritonavir) increases Tenofovir concentrations, requiring monitoring.

Product-Specific Constraints: The fixed-dose design prevents necessary dose adjustments, thus the medicine is not recommended for patients with estimated Creatinine Clearance below 50 mL/min or those with moderate to severe hepatic impairment. Concurrent or recent use of nephrotoxic drugs must be avoided due to the renal elimination pathway of the Tenofovir component. Administration on an empty stomach is recommended to mitigate the increased Efavirenz exposure associated with food ingestion.

Mechanism of Action

Atripla is a combination of three antiretroviral components that undergo intracellular conversion into their active triphosphate forms within the host cell. These triphosphates function as competitive inhibitors and alternate substrates for the reverse transcriptase (RT) enzyme, a key component in HIV-1 replication

. This molecular interaction results in the non-obligate chain termination of the nascent proviral DNA strand, thereby preventing the complete transcription of the viral genome. By inhibiting the RT enzyme's activity, the mechanism limits the subsequent integration of viral DNA into the host cell genome. This cellular process leads to a reduced capacity for viral particle production and lessens the viral destruction of host CD4+ T-cells at the system level.

Dosage and Administration Information

How to Use Atripla Access

This section describes the standard administration protocol for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), focusing on the principles of use and dosage schedules.

Administration Protocol and Dosing Schedule

Feature Instruction
Route of Administration The medicine is taken orally as a film-coated tablet, swallowed whole with water.
Standard Daily Dose The regimen consists of one fixed-dose tablet once daily. This tablet contains the full required dose of all three active components.
Timing and Context Dosing must occur on an empty stomach. It is generally advised that the dose be taken preferably at bedtime to help improve the tolerability of nervous system symptoms.

Usage Constraints and Population Rules

Atripla Access is typically used as a complete regimen for the long-term management of HIV-1 infection. The medication is for patients who are 12 years of age or older and weigh at least 40 kg (approx 88 lbs), who should receive the standard adult dosage.

Due to its fixed-dose combination, the tablet is not recommended for patients with moderate or severe hepatic impairment or those with estimated creatinine clearance (CrCl) below 50 mL/min.

If an administration is forgotten, the protocol for a missed dose is to take it if less than 12 hours have passed since the usual time. If more than 12 hours have passed, the missed dose must be skipped entirely, and the regular schedule should be resumed the following day. The medicine must not be co-administered with other products containing the same active ingredients.

Recent Clinical Evidence

Atripla Access: Recent Clinical Evidence

Clinical research has extensively evaluated the fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate (the active components in Atripla) as a complete regimen for treating HIV-1 infection in adults and pediatric patients weighing at least 40 kg. Studies confirm the regimen’s role as part of a standard initial therapy option.

Research focuses primarily on measuring virologic response, defined as achieving or maintaining HIV-1 RNA levels below detectable limits. Early trials established that the combination therapy provided a sustained suppression of viral load in treatment-naïve adult patients, a finding that supports its use as a first-line treatment option in guidelines published by authoritative health organizations.

Key Research Findings

  • Virologic Suppression: Large-scale clinical trials demonstrated that a high percentage of patients initiating this single-pill regimen achieved and maintained HIV-1 RNA suppression (less than 50 copies/mL) throughout the study periods (typically 48 to 96 weeks).
  • Immunologic Restoration: Research consistently shows that the combination therapy leads to increases in CD4+ cell counts, an indicator of immune system recovery, particularly during the first year of treatment.

Tolerability and Long-Term Studies

Long-term observational studies have investigated the tolerability profile of the components, focusing on potential renal (kidney) and bone effects associated with tenofovir disoproxil fumarate. While generally well-tolerated, studies have tracked changes in bone mineral density (BMD) and renal function markers, such as creatinine clearance, over extended periods. These findings inform contemporary clinical monitoring practices.

Key Studies & References Efavirenz, emtricitabine, and tenofovir disoproxil fumarate (Atripla): a single-pill once-daily regimen for the treatment of HIV-1 infection

Frequently Asked Questions (FAQ)

Common questions about Atripla Access (FAQ)

Q: What is the shelf life or expiration date of Atripla Access?

The official product information states that the medicine has a defined expiration date which you can find printed on the original package or bottle. To maintain its stability, regulatory guidance indicates the product should be kept in its original container, ensure the container is tightly closed, and stored at 25 C (77 F). The medication should not be used past the printed date.

Q: Is it safe to crush or chew the Atripla tablets?

Regulatory documents describe the method of administration for this medicine as an oral film-coated tablet. To ensure the drug's intended action, the tablet is generally intended to be swallowed whole with water. Furthermore, official instructions for the disposal of the medicine explicitly state that the tablets must not be crushed.

Q: Does Atripla interact with over-the-counter pain relievers like acetaminophen (Tylenol)?

Official drug labeling specifies substances that are either restricted or those that have no expected interaction with Atripla's active components. Acetaminophen is not typically listed as a contraindicated drug, and is often mentioned in regulatory documents as having no expected pharmacokinetic interaction with the key components (Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate).

Q: How long will it take for my viral load to become undetectable on Atripla?

Studies and official information indicate that this combination therapy leads to effective viral load suppression (HIV-1 RNA levels below detectable limits) in a high percentage of patients. Clinical trials tracked this success over periods ranging from 48 to 96 weeks. The time it takes to achieve viral suppression is known to be variable among individuals.

How should Atripla Access be stored and disposed of?

Storage and Disposal Requirements for Atripla Tablets

The storage and handling of Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets are strictly defined in official regulatory labeling to maintain product stability and ensure safety.

Official Storage Conditions

Requirement Condition (Regulatory Standard)
Required Temperature Store at 25°C (77°F); excursions permitted from 15°C to 30°C.
Moisture Protection Keep in the original container with the silica gel desiccant.
Container Integrity The container must be kept tightly closed.
Child Safety Store medication out of the reach of children.

Disposal Instructions

Unused or expired medication should be disposed of using a drug take-back program or an authorized collection site. If a take-back program is unavailable, the official alternative procedure is to mix the whole tablets with an undesirable substance (such as used coffee grounds) and seal the mixture in a bag before placing it in the trash. The tablets must not be crushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Atripla Access found in:

A-Z Index: